Recent progress in the identification and development of InhA direct inhibitors of mycobacterium tuberculosis

Mini-Reviews in Medicinal Chemistry

Volumn 10, Issue 3, 2010, Pages 182-193

  Lu, X Y ^a   You, Q D ^a   Chen, Y D ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Anti tubercular agents; Direct inhibitors; Drug design; Indirect inhibitors; INH NAD adduct; InhA; Isoniazid; KatG

Indexed keywords

ENOYL ACYL CARRIER PROTEIN REDUCTASE (NADH); ETHIONAMIDE; FATTY ACID SYNTHASE; GENZ 10850; GENZ 8575; INHA DIRECT INHIBITOR; ISONIAZID; KATG PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE; PIPERIDINE DERIVATIVE; PROTIONAMIDE; PYRAZOLE DERIVATIVE; PYRROLIDINE DERIVATIVE; TRICLOSAN; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; BACTERIAL PROTEIN; DRUG DERIVATIVE; ENZYME INHIBITOR; INHA PROTEIN, MYCOBACTERIUM; OXIDOREDUCTASE;

ARTICLE; BINDING AFFINITY; BIOAVAILABILITY; CHEMICAL INTERACTION; COMBINATORIAL LIBRARY; COMPLEX FORMATION; CONFORMATION; CRYSTAL STRUCTURE; DIPHENYL ETHER DERIVATIVE; DRUG STABILITY; ENANTIOMER; FATTY ACID SYNTHESIS; HIGH THROUGHPUT SCREENING; HUMAN; IC 50; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR DOCKING; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; STRUCTURE ACTIVITY RELATION; TUBERCULOSIS; CHEMISTRY; DRUG ANTAGONISM; ENZYMOLOGY; METABOLISM; REVIEW;

ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; ENZYME INHIBITORS; ISONIAZID; MYCOBACTERIUM TUBERCULOSIS; NAD; OXIDOREDUCTASES; PYRAZOLES; TRICLOSAN;

EID: 84863402494     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/138955710791185064     Document Type: Article

References (97)

1. World Health Organization: Fact Sheet No 104: tuberculosis. WHO Fact Sheets. Geneva: WHO, 2002.
2. Nunn, P.; Williams, B.; Floyd, K.; Dye, C.; Elzinga, G.; Raviglione, M. Tuberculosis control in the era of HIV. Nat. Rev. Immunol., 2005, 5, 819-26.
3. Global Alliance for Tuberculosis Drug Development. Tuberculosis. Scientific blueprint for tuberculosis drug development. Tuberculosis, 2001, 81(Suppl.), 1-52.
4. Ellner, J.J.; Goldberger, M.J.; Parenti, D.M. Mycobacterium avium infection and AIDS: a therapeutic dilemma in rapid evolution. J. Infect. Dis., 1991, 163, 1326-35.
5. Cole, S.T.; Brosch, R.; Parkhill, J.; Garnier, T.; Churcher, C.; Harris, D.; Gordon, S.V.; Eiglmeier, K.; Gas, S.; Barry, C.E., 3rd; Tekaia, F.; Badcock, K.; Basham, D.; Brown, D.; Chillingworth, T.; Connor, R.; Davies, R.; Devlin, K.; Feltwell, T.; Gentles, S.; Hamlin, N.; Holroyd, S.; Hornsby, T.; Jagels, K.; Krogh, A.; McLean, J.; Moule, S.; Murphy, L.; Oliver, K.; Osborne, J.; Quail, M.A.; Rajandream, M.A.; Rogers, J.; Rutter, S.; Seeger, K.; Skelton, J.; Squares, R.; Squares, S.; Sulston, J.E.; Taylor, K.; Whitehead, S.; Barrell, B.G. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature, 1998, 393, 537-44.
6. Brennan, P.J. and Nikaido, H. The envelope of mycobacteria. Annu. Rev. Biochem., 1995, 64, 29-63.
7. Lee, R.E.; Brennan, P.J.; Besra, G.S. Mycobacterium tuberculosis cell envelope. Curr. Top. Microbiol. Immunol., 1996, 215, 1-27.
8. Russell, D.G.; Mwandumba, H.C.; Rhoades, E.E. Mycobacterium and the coat of many lipids. J. Cell. Biol., 2002, 158, 421-6.
9. Liu, J.; Barry, C.E., 3rd; Besra, G.S.; Nikaido, H. Mycolic acid structure determines the fluidity of the mycobacterial cell wall. J. Biol. Chem., 1996, 271, 29545-51.
10. Tonge, P.J. Another brick in the wall. Nat. Struct. Biol., 2000, 7, 94-6.
11. Barry, C.E., III; Lee, R.E.; Mdluli, K.; Sampson, A.E.; Schroeder, B.G.; Slayden, R.A.; Yuan, Y. Mycolic acids: structure, biosynthesis and physiological functions. Prog. Lipid Res., 1998, 37, 143-79.
12. Pasqualoto, K.F.; Ferreira, E.I. An approach for the rational design of new antituberculosis agents. Curr. Drug Targets., 2001, 2, 427-37.
13. Banerjee, A.; Dubnau, E.; Quemard, A.; Balasubramanian, V.; Um, K.S.; Wilson, T.; Collins, D.; de Lisle, G.; Jacobs, W.R. Jr. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science, 1994, 263, 227-30.
14. Dessen, A.; Quemard, A.; Blanchard, J.S.; Jacobs, W.R., Jr.; Sacchettini, J.C. Crystal structure and function of the isoniazid target of Mycobacterium tuberculosis. Science, 1995, 267, 1638-41.
15. Scior, T.; Garces-Eisele, S.J. Isoniazid is not a lead compound for its pyridyl ring derivatives, isonicotinoyl amides, hydrazides, and hydrazones: a critical review. Curr. Med. Chem., 2006, 13, 2205-19.
16. Parikh, S.L.; Xiao, G.; Tonge, P.J. Inhibition of InhA, the enoyl reductase from Mycobacterium tuberculosis, by triclosan and isoniazid. Biochemistry, 2000, 39, 7645-50.
17. Rawat, R.; Whitty, A.; Tonge, P.J. The isoniazid-NAD adduct is a slow, tight-binding inhibitor of InhA, the Mycobacterium tuberculosis enoyl reductase: adduct affinity and drug resistance. Proc. Natl. Acad. Sci. USA, 2003, 100, 13881-6.
18. Tong, P.J.; Kisker C.; Slayden, R.A. Development of modern InhA inhibitors to combat drug resistant strains of Mycobacterium tuberculosis. Curr. Top. Med. Chem., 2007, 7, 489-98.
19. Kuo, M.R.; Morbidoni, H.R.; Alland, D.; Sneddon, S.F.; Gourlie, B.B.; Staveski, M.M.; Leonard, M.; Gregory, J.S.; Janjigian, A.D.; Yee, C.; Musser, J.M.; Kreiswirth, B.; Iwamoto, H.; Perozzo, R.; Jacobs, W.R., Jr.; Sacchettini, J.C.; Fidock, D.A. Targeting tuberculosis and malaria through inhibition of Enoyl reductase: compound activity and structural data. J. Biol. Chem., 2003, 278, 20851-9.
20. He, X.; Alian, A.; Stroud, R.; Ortiz de Montellano, P.R. Pyrrolidine carboxamides as a novel class of inhibitors of enoyl acyl carrier protein reductase from Mycobacterium tuberculosis. J. Med. Chem., 2006, 49, 6308-23.
21. He, X.; Alian, A.; Ortiz de Montellano, P.R. Inhibition of the Mycobacterium tuberculosis enoyl acyl carrier protein reductase InhA by arylamides. Bioorg. Med. Chem., 2007, 15, 6649-58.
22. Wall, M.D.; Oshin, M.; Chung, G.A.; Parkhouse, T.; Gore, A.; Herreros, E.; Cox, B.; Duncan, K.; Evans, B.; Everett, M.; Mendoza, A. Evaluation of N-(phenylmethyl)-4-[5-(phenylmethyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]p yridin-4-yl]benzamide inhibitors of Mycobacterium tuberculosis growth. Bioorg. Med. Chem. Lett., 2007, 17, 2740-4.
23. Fox, H.H. The chemical approach to the control of tuberculosis. Science, 1952, 116, 129-34.
24. Pansy, F.; Stander, H.; Donovick, R. In vitro studies on isonicotinic acid hydrazide. Am. Rev. Tuberc., 1952, 65, 761-4.
25. Zhang, Y.; Heym, B.; Allen, B.; Young, D.; Cole, S. The catalaseperoxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature, 1992, 358, 591-3.
26. Ghiladi, R.A.; Medzihradszky, K.F.; Rusnak, F.M.; Ortiz de Montellano, P.R. Correlation between isoniazid resistance and superoxide reactivity in Mycobacterium tuberculosis KatG. J. Am. Chem. Soc., 2005, 127, 13428-42.
27. Johnsson, K.; Schultz, P.G. Mechanistic Studies of the Oxidation of Isoniazid by the Catalase Peroxidase from Mycobacterium tuberculosis. J. Am. Chem. Soc., 1994, 116, 7425-6.
28. Johnsson, K.; King, D.S.; Schultz, P.G. Studies on the mechanism of action of isoniazid and ethionamide in the chemotherapy of tuberculosis. J. Am. Chem. Soc., 1995, 117, 5009-10.
29. Basso, L.A.; Zheng, R.J.; Blanchard, J.S. Kinetics of Inactivation of WT and C243S Mutant of Mycobacterium tuberculosis Enoyl Reductase by Activated Isoniazid. J. Am. Chem. Soc., 1996, 118, 11301-2.
30. Scior, T.; Meneses Morales, I.; Garces Eisele, S.J.; Domeyer, D.; Laufer, S. Antitubercular isoniazid and drug resistance of Mycobacterium tuberculosis--a review. Arch. Pharm. Pharm. Med. Chem., 2002, 355, 511-25.
31. Rozwarski, D.A.; Grant, G.A.; Barton, D.H.; Jacobs, W.R., Jr.; Sacchettini, J.C. Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis. Science, 1998, 279, 98-102.
32. Lei, B.; Wei, C.J.; Tu, S.C. Action mechanism of antitubercular isoniazid. Activation by Mycobacterium tuberculosis KatG, isolation, and characterization of inha inhibitor. J. Biol. Chem., 2000, 275, 2520-6.
33. Stigliani, J.L.; Arnaud, P.; Delaine, T.; Bernardes-Genisson, V.; Meunier, B.; Bernadou, J. Binding of the tautomeric forms of isoniazid-NAD adducts to the active site of the Mycobacterium tuberculosis enoyl-ACP reductase (InhA): a theoretical approach. J. Mol. Graph. Model., 2008, 27, 536-45.
34. Stoeckle, M.Y.; Guan, L.; Riegler, N.; Weitzman, I.; Kreiswirth, B.; Kornblum, J.; Laraque, F.; Riley, L.W. Catalase-peroxidase gene sequences in isoniazid-sensitive and -resistant strains of Mycobacterium tuberculosis from New York City. J. Infect. Dis., 1993, 168, 1063-5.
35. Musser, J.M.; Kapur, V.; Williams, D.L.; Kreiswirth, B.N.; van Soolingen, D.; van Embden, J.D. Characterization of the catalaseperoxidase gene (katG) and inhA locus in isoniazid-resistant and -susceptible strains of Mycobacterium tuberculosis by automated DNA sequencing: restricted array of mutations associated with drug resistance. J. Infect. Dis., 1996, 173, 196-202.
36. Ramaswamy, S.V.; Reich, R.; Dou, S.J.; Jasperse, L.; Pan, X.; Wanger, A.; Quitugua, T.; Graviss, E.A. Single nucleotide polymorphisms in genes associated with isoniazid resistance in Mycobacterium tuberculosis. Antimicrob. Agents Chemother., 2003, 47, 1241-50.
37. Zhao, X.; Yu, H.; Yu, S.; Wang, F.; Sacchettini, J.C.; Magliozzo, R.S. Hydrogen peroxide-mediated isoniazid activation catalyzed by Mycobacterium tuberculosis catalase-peroxidase (KatG) and its S315T mutant. Biochemistry, 2006, 45, 4131-40.
38. Basso, L.A.; Zheng, R.; Musser, J.M.; Jacobs, W.R., Jr.; Blanchard, J.S. Mechanisms of isoniazid resistance in Mycobacterium tuberculosis: enzymatic characterization of enoyl reductase mutants identified in isoniazid-resistant clinical isolates. J. Infect. Dis., 1998, 178, 769-75.
39. Mdluli, K.; Slayden, R.A.; Zhu, Y.; Ramaswamy, S.; Pan, X.; Mead, D.; Crane, D.D.; Musser, J.M.; Barry, C.E., 3rd. Inhibition of a Mycobacterium tuberculosis beta-ketoacyl ACP synthase by isoniazid. Science, 1998, 280, 1607-10.
40. Vilcheze, C.; Wang, F.; Arai, M.; Hazbon, M.H.; Colangeli, R.; Kremer, L.; Weisbrod, T.R.; Alland, D.; Sacchettini, J.C.; Jacobs, W.R., Jr. Transfer of a point mutation in Mycobacterium tuberculosis inhA resolves the target of isoniazid. Nat. Med., 2006, 12, 1027-9.
41. Oliveira, J.S.; Pereira, J.H.; Canduri, F.; Rodrigues, N.C.; de Souza, O.N.; de Azevedo, W.F., Jr.; Basso, L.A.; Santos, D.S. Crystallographic and pre-steady-state kinetics studies on binding of NADH to wild-type and isoniazid-resistant enoyl-ACP(CoA) reductase enzymes from Mycobacterium tuberculosis. J. Mol. Biol., 2006, 359, 646-66.
42. Dias, M.V.; Vasconcelos, I.B.; Prado, A.M.; Fadel, V.; Basso, L.A.; de Azevedo, W.F., Jr.; Santos, D.S. Crystallographic studies on the binding of isonicotinyl-NAD adduct to wild-type and isoniazid resistant 2-trans-enoyl-ACP (CoA) reductase from Mycobacterium tuberculosis. J. Struct. Biol., 2007, 159, 369-80.
43. Kruh, N.A.; Rawat, R.; Ruzsicska, B.P.; Tonge, P.J. Probing mechanisms of resistance to the tuberculosis drug isoniazid: Conformational changes caused by inhibition of InhA, the enoyl reductase from Mycobacterium tuberculosis. Protein Sci., 2007, 16, 1617-27.
44. Yajko, D.M.; Nassos, P.S.; Hadley, W.K. Therapeutic implications of inhibition versus killing of Mycobacterium avium complex by antimicrobial agents. Antimicrob. Agents Chemother., 1987, 31, 117-20.
45. Fajardo, T.T.; Guinto, R.S.; Cellona, R.V.; Abalos, R.M.; Dela Cruz, E.C.; Gelber, R.H. A clinical trial of ethionamide and prothionamide for treatment of lepromatous leprosy. Am. J. Trop. Med. Hyg., 2006, 74, 457-61.
46. Centers for Disease Control and Prevention. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs. Ann. Pharmacother., 2006, 40, 1007-8.
47. Takayama, K.; Wang, L.; David, H.L. Effect of isoniazid on the in vivo mycolic acid synthesis, cell growth, and viability of Mycobacterium tuberculosis. Antimicrob. Agents Chemother., 1972, 2, 29-35.
48. Winder, F.G.; Collins, P.B.; Whelan, D. Effects of ethionamide and isoxyl on mycolic acid synthesis in Mycobacterium tuberculosis BCG. J. Gen. Microbiol., 1971, 66, 379-80.
49. Morlock, G.P.; Metchock, B.; Sikes, D.; Crawford, J.T.; Cooksey, R.C. ethA, inhA, and katG loci of ethionamide-resistant clinical Mycobacterium tuberculosis isolates. Antimicrob. Agents Chemother., 2003, 47, 3799-805.
50. Fattorini, L.; Iona, E.; Ricci, M.L.; Thoresen, O.F.; Orru, G.; Oggioni, M.R.; Tortoli, E.; Piersimoni, C.; Chiaradonna, P.; Tronci, M.; Pozzi, G.; Orefici, G. Activity of 16 antimicrobial agents against drug-resistant strains of Mycobacterium tuberculosis. Microb. Drug Resist., 1999, 5, 265-70.
51. DeBarber, A.E.; Mdluli, K.; Bosman, M.; Bekker, L.G.; Barry, C.E., 3rd. Ethionamide activation and sensitivity in multidrugresistant Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. USA, 2000, 97, 9677-82.
52. Baulard, A.R.; Betts, J.C.; Engohang-Ndong, J.; Quan, S.; McAdam, R.A.; Brennan, P.J.; Locht, C.; Besra, G.S. Activation of the pro-drug ethionamide is regulated in mycobacteria. J. Biol. Chem., 2000, 275, 28326-31.
53. Wang, F.; Langley, R.; Gulten, G.; Dover, L.G.; Besra, G.S.; Jacobs, W.R., Jr.; Sacchettini, J.C. Mechanism of thioamide drug action against tuberculosis and leprosy. J. Exp. Med., 2007, 204, 73-8.
54. Nguyen, M.; Quémard, A.; Broussy, S.; Bernadou, J.; Meunier, B. Mn(III) pyrophosphate as an efficient tool for studying the mode of action of isoniazid on the InhA protein of Mycobacterium tuberculosis. Antimicrob. Agents Chemother., 2002, 46, 2137-44.
55. Broussy, S.; Bernardes-Genisson, V.; Quemard, A.; Meunier, B.; Bernadou, J. The first chemical synthesis of the core structure of the benzoylhydrazine-NAD adduct, a competitive inhibitor of the Mycobacterium tuberculosis enoyl reductase. J. Org. Chem., 2005, 70, 10502-10.
56. Argyrou, A.; Vetting, M.W.; Blanchard, J.S. New insight into the mechanism of action of and resistance to isoniazid: interaction of Mycobacterium tuberculosis enoyl-ACP reductase with INHNADP. J. Am. Chem. Soc., 2007, 129, 9582-3.
57. Delaine, T.; Bernardes-Genisson, V.; Meunier, B.; Bernadou, J. Synthesis of the isonicotinoylnicotinamide scaffolds of the naturally occurring isoniazid-NAD(P) adducts. J. Org. Chem., 2007, 72, 675-8.
58. Nguyen, M.; Claparols, C.; Bernadou, J.; Meunier, B. A fast and efficient metal-mediated oxidation of isoniazid and identification of isoniazid-NAD(H) adducts. ChemBioChem, 2001, 2, 877-83.
59. Wilming, M.; Johnsson, K. Spontaneous Formation of the Bioactive Form of the Tuberculosis Drug Isoniazid. Angew. Chem. Int. Ed. Engl., 1999, 38, 2588-90.
60. 13C NMR characterization of hemiamidal isoniazid-NAD(H) adducts as possible inhibitors of InhA reductase of Mycobacterium tuberculosis. Chemistry, 2003, 9, 2034-8.
61. Bonnac, L.; Gao, G.Y.; Chen, L.; Felczak, K.; Bennett, E.M.; Xu, H.; Kim, T.; Liu, N.; Oh, H.; Tonge, P.J.; Pankiewicz, K.W. Synthesis of 4-phenoxybenzamide adenine dinucleotide as NAD analogue with inhibitory activity against enoyl-ACP reductase (InhA) of Mycobacterium tuberculosis. Bioorg. Med. Chem. Lett., 2007, 17, 4588-91.
62. Zatorski, A.; Watanabe, K.A.; Carr, S.F.; Goldstein, B.M.; Pankiewicz, K.W. Chemical synthesis of benzamide adenine dinucleotide: inhibition of inosine monophosphate dehydrogenase (types I and II). J. Med. Chem., 1996, 39, 2422-6.
63. Pankiewicz, K.W.; Lesiak, K.; Zatorski, A.; Goldstein, B.M.; Carr, S.F.; Sochacki, M.; Majumdar, A.; Seidman, M.; Watanabe, K.A. The practical synthesis of a methylenebisphosphonate analogue of benzamide adenine dinucleotide: inhibition of human inosine monophosphate dehydrogenase (type I and II). J. Med. Chem., 1997, 40, 1287-91.
64. Pankiewicz, K.W.; Lesiak-Watanabe, K.B.; Watanabe, K.A.; Patterson, S.E.; Jayaram, H.N.; Yalowitz, J.A.; Miller, M.D.; Seidman, M.; Majumdar, A.; Prehna, G.; Goldstein, B.M. Novel mycophenolic adenine bis(phosphonate) analogues as potential differentiation agents against human leukemia. J. Med. Chem., 2002, 45, 703-12.
65. McMurry, L.M.; Oethinger, M.; Levy, S.B. Triclosan targets lipid synthesis. Nature, 1998, 394, 531-2.
66. Roujeinikova, A.; Levy, C.W.; Rowsell, S.; Sedelnikova, S.; Baker, P.J.; Minshull, C.A.; Mistry, A.; Colls, J.G.; Camble, R.; Stuitje, A.R.; Slabas, A.R.; Rafferty, J.B.; Pauptit, R.A.; Viner, R.; Rice, D.W. Crystallographic analysis of triclosan bound to enoyl reductase. J. Mol. Biol., 1999, 294, 527-35.
67. Levy, C.W.; Roujeinikova, A.; Sedelnikova, S.; Baker, P.J.; Stuitje, A.R.; Slabas, A.R.; Rice, D.W.; Rafferty, J.B. Molecular basis of triclosan activity. Nature, 1999, 398, 383-4.
68. Ward, W.H.; Holdgate, G.A.; Rowsell, S.; McLean, E.G.; Pauptit, R.A.; Clayton, E.; Nichols, W.W.; Colls, J.G.; Minshull, C.A.; Jude, D.A.; Mistry, A.; Timms, D.; Camble, R.; Hales, N.J.; Britton, C.J.; Taylor, I.W. Kinetic and structural characteristics of the inhibition of enoyl (acyl carrier protein) reductase by triclosan. Biochemistry, 1999, 38, 12514-25.
69. Heath, R.J.; Rubin, J.R.; Holland, D.R.; Zhang, E.; Snow, M.E.; Rock, C.O. Mechanism of triclosan inhibition of bacterial fatty acid synthesis. J. Biol. Chem., 1999, 274, 11110-4.
70. Lu, H.; Tonge, P.J. Inhibitors of FabI, an enzyme drug target in the bacterial fatty acid biosynthesis pathway. Acc. Chem. Res., 2008, 41, 11-20.
71. Baldock, C.; Rafferty, J.B.; Sedelnikova, S.E.; Baker, P.J.; Stuitje, A.R.; Slabas, A.R.; Hawkes, T.R.; Rice, D.W. A mechanism of drug action revealed by structural studies of enoyl reductase. Science, 1996, 274, 2107-10.
72. Levy, C.W.; Baldock, C.; Wallace, A.J.; Sedelnikova, S.; Viner, R.C.; Clough, J.M.; Stuitje, A.R.; Slabas, A.R.; Rice, D.W.; Rafferty, J.B. A study of the structure-activity relationship for diazaborine inhibition of Escherichia coli enoyl-ACP reductase. J. Mol. Biol., 2001, 309, 171-80.
73. Chhibber, M.; Kumar, G.; Parasuraman, P.; Ramya, T.N.; Surolia, N.; Surolia, A. Novel diphenyl ethers: design, docking studies, synthesis and inhibition of enoyl ACP reductase of Plasmodium falciparum and Escherichia coli. Bioorg. Med. Chem., 2006, 14, 8086-98.
74. Miller, W.H.; Seefeld, M.A.; Newlander, K.A.; Uzinskas, I.N.; Burgess, W.J.; Heerding, D.A.; Yuan, C.C.K.; Head, M.S.; Payne, D.J.; Rittenhouse, S.F.; Moore, T.D.; Pearson, S.C.; Berry, V.; DeWolf, W.E., Jr.; Keller, P.M.; Polizzi, B.J.; Qiu, X.; Janson, C.A.; Huffman, W.F. Discovery of aminopyridine-based inhibitors of bacterial enoyl-ACP reductase (FabI). J. Med. Chem., 2002, 45, 3246-56.
75. Seefeld, M.A.; Miller, W.H.; Newlander, K.A.; Burgess, W.J.; Payne, D.J.; Rittenhouse, S.F.; Moore, T.D.; DeWolf, W.E., Jr.; Keller, P.M.; Qiu, X.; Janson, C.A.; Vaidya, K.; Fosberry, A.P.; Smyth, M.G.; Jaworski, D.D.; Slater-Radosti, C.; Huffman, W.F. Inhibitors of bacterial enoyl acyl carrier protein reductase (FabI): 2,9-disubstituted 1,2,3,4-tetrahydropyrido[3,4-b]indoles as potential antibacterial agents. Bioorg. Med. Chem. Lett., 2001, 11, 2241-4.
76. Seefeld, M.A.; Miller, W.H.; Newlander, K.A.; Burgess, W.J.; DeWolf, W.E., Jr.; Elkins, P.A.; Head, M.S.; Jakas, D.R.; Janson, C.A.; Keller, P.M.; Manley, P.J.; Moore, T.D.; Payne, D.J.; Pearson, S.; Polizzi, B.J.; Qiu, X.; Rittenhouse, S.F.; Uzinskas, I.N.; Wallis, N.G.; Huffman, W.F. Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK. J. Med. Chem., 2003, 46, 1627-35.
77. Payne, D.J.; Miller, W.H.; Berry, V.; Brosky, J.; Burgess, W.J.; Chen, E.; DeWolf Jr, W.E., Jr.; Fosberry, A.P.; Greenwood, R.; Head, M.S.; Heerding, D.A.; Janson, C.A.; Jaworski, D.D.; Keller, P.M.; Manley, P.J.; Moore, T.D.; Newlander, K.A.; Pearson, S.; Polizzi, B.J.; Qiu, X.; Rittenhouse, S.F.; Slater-Radosti, C.; Salyers, K.L.; Seefeld, M.A.; Smyth, M.G.; Takata, D.T.; Uzinskas, I.N.; Vaidya, K.; Wallis, N.G.; Winram, S.B.; Yuan, C.C.; Huffman, W.F. Discovery of a novel and potent class of FabI-directed antibacterial agents. Antimicrob. Agents Chemother., 2002, 46, 3118-24.
78. Park, H.S.; Yoon, Y.M.; Jung, S.J.; Yun, I.N.; Kim, C.M.; Kim, J.M.; Kwak, J.H. CG400462, a new bacterial enoyl-acyl carrier protein reductase (FabI) inhibitor. Int. J. Antimicrob. Agents, 2007, 30, 446-51.
79. Ling, L.L.; Xian, J.; Ali, S.; Geng, B.; Fan, J.; Mills, D.M.; Arvanites, A.C.; Orgueira, H.; Ashwell, M.A.; Carmel, G.; Xiang, Y.; Moir, D.T. Identification and characterization of inhibitors of bacterial enoyl-acyl carrier protein reductase. Antimicrob. Agents Chemother., 2004, 48, 1541-7.
80. Kitagawa, H.; Kumura, K.; Takahata, S.; Iida, M.; Atsumi, K. 4-Pyridone derivatives as new inhibitors of bacterial enoyl-ACP reductase FabI. Bioorg. Med. Chem., 2007, 15, 1106-16.
81. Yum, J.H.; Kim, C.K.; Yong, D.; Lee, K.; Chong, Y.; Kim, C.M.; Kim, J.M.; Ro, S.; Cho, J.M. In vitro activities of CG400549, a novel FabI inhibitor, against recently isolated clinical staphylococcal strains in Korea. Antimicrob. Agents Chemother., 2007, 51, 2591-3.
82. McMurry, L.M.; McDermott, P.F.; Levy, S.B. Genetic evidence that InhA of Mycobacterium smegmatis is a target for triclosan. Antimicrob. Agents Chemother., 1999, 43, 711-3.
83. Rozwarski, D.A.; Vilcheze, C.; Sugantino, M.; Bittman, R.; Sacchettini, J.C. Crystal structure of the Mycobacterium tuberculosis enoyl-ACP reductase, InhA, in complex with NAD+ and a C16 fatty acyl substrate. J. Biol. Chem., 1999, 274, 15582-9.
84. Sullivan, T.J.; Truglio, J.J.; Boyne, M.E.; Novichenok, P.; Zhang, X.; Stratton, C.F.; Li, H.J.; Kaur, T.; Amin, A.; Johnson, F.; Slayden, R.A.; Kisker, C.; Tonge, P.J. High affinity InhA inhibitors with activity against drug-resistant strains of Mycobacterium tuberculosis. ACS. Chem. Biol., 2006, 1, 43-53.
85. Sivaraman, S.; Zwahlen, J.; Bell, A.F.; Hedstrom, L.; Tonge, P.J. Structure-activity studies of the inhibition of FabI, the enoyl reductase from Escherichia coli, by triclosan: kinetic analysis of mutant FabIs. Biochemistry, 2003, 42, 4406-13.
86. Boyne, M.E.; Sullivan, T.J.; amEnde, C.W.; Lu, H.; Gruppo, V.; Heaslip, D.; Amin, A.G.; Chatterjee, D.; Lenaerts, A.; Tonge, P.J.; Slayden, R.A. Targeting fatty acid biosynthesis for the development of novel chemotherapeutics against Mycobacterium tuberculosis: evaluation of A-ring-modified diphenyl ethers as highaffinity InhA inhibitors. Antimicrob. Agents Chemother., 2007, 51, 3562-7.
87. am Ende, C.W.; Kundson, S.E.; Liu, N.; Childs, J.; Sullivan, T.J.; Boyne, M.; Xu, H.; Knudson, D.L.; Johnson, F.; Peloquin, C.A.; Slayden, R.A.; Tonge, P.J. Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors. Bioorg. Med. Chem. Lett., 2008, 18, 3029-33.
88. Kini, S.G.; Bhat, A.R.; Bryant, B.; Williamson, J.S.; Dayan, F.E. Synthesis, antitubercular activity and docking study of novel cyclic azole substituted diphenyl ether derivatives. Eur. J. Med. Chem., 2009, 44, 492-500.
89. Wu, C.Y.; Chang, C.F.; Chen, J.S.; Wong, C.H.; Lin, C.H. Rapid diversity-oriented synthesis in microtiter plates for in situ screening: discovery of potent and selective alpha-fucosidase inhibitors. Angew. Chem. Int. Ed. Engl., 2003, 42, 4661-4.
90. Stocker, F.B.; Fordice, M.W.; Larson, J.K.; Thorstenson, J.H. Some 4-Aryl-4,5,6,7-tetrahydroimidazo[4,5-c]pyridines Derived from Histamine. J. Org. Chem., 1966, 31, 2380-3.
91. Stocker, F.B.; Evans, A.J. Synthesis of 6-aryl-4,5-dibenzamido-1,2,3,6-tetrahydropyridines. J. Org. Chem., 1990, 55, 3370-3.
92. Kumar, A.; Siddiqi, M.I. CoMFA based de novo design of pyrrolidine carboxamides as inhibitors of enoyl acyl carrier protein reductase from Mycobacterium tuberculosis. J. Mol. Model., 2008, 14, 923-35.
93. Subba Rao, G.; Vijayakrishnan, R.; Kumar, M. Structure-based design of a novel class of potent inhibitors of InhA, the enoyl acyl carrier protein reductase from Mycobacterium tuberculosis: a computer modelling approach. Chem. Biol. Drug Des., 2008, 72, 444-9.
94. Seifert, M.H.; Lang, M. Essential factors for successful virtual screening. Mini-Rev. Med. Chem., 2008, 7, 63-72.
95. The crystal structure of the InhA complex were downloaded from the Protein Data Bank (entry 2H7M) and used for initial docking studies. http://www.rcsb.org/pdb/explore.do?structureId=2H7M
96. Jones, G.; Willett, P.; Glen, R.C.; Leach, A.R.; Taylor, R. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol., 1997, 267, 727-48.
97. Lipinski, C.A.; Lombardo, F.; Dominy, B.W.; Feeney, P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev., 2001, 46, 3-26.